Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mobic · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Meloxicam Tablets 15 mg |
| 2 | ACTIVE_COMPARATOR | Mobic® Tablets 15 mg |
| Name | Type | Description |
|---|---|---|
| Meloxicam Tablets 15 mg | DRUG | 15mg, single dose fasting |
| Mobic® Tablets 15 mg | DRUG | 15mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administrati...
Mobic is a small molecule drug being developed by Viatris Inc. for use in healthy individuals. It is currently in Phase 1 clinical development, with studies evaluating its pharmacokinetics and bioequivalence in healthy volunteers.
Mobic is developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The drug is currently in Phase 1 clinical development.
Mobic is in Phase 1 clinical development. It has completed two Phase 1 trials, both of which were conducted in healthy volunteers in the United States.
Mobic has completed two Phase 1 clinical trials: NCT00649077, a fasting study of Meloxicam Tablets 15 mg and Mobic Tablets 15 mg, and NCT00649675, a food study of the same formulations. Both trials enrolled healthy volunteers in the United States.
Mobic is a brand name for meloxicam tablets. The clinical trials for Mobic compare Meloxicam Tablets 15 mg with Mobic Tablets 15 mg, indicating they are the same drug substance.